A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade

This Study is
No Longer Enrolling

Details
Age

Adult

Eligibility

Must have a lesion of sufficient size to support injection of complete first dose of mRNA-2752

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 18-1526

More information available at ClinicalTrials.gov: NCT03739931

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers